Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis

Condition(s) targeted: Methamphetamine-induced Psychosis

Intervention: Diazepam (Drug); Vitamin B1-6-12 (Dietary Supplement); Stugeron (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Chulalongkorn University

Official(s) and/or principal investigator(s):
Viroj Verachai, M.D., Principal Investigator, Affiliation: Thanyarak Institute on Drug Abuse

The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.

Official title: Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome:

Positive and Negative Syndrome Scale

Positive and Negative Syndrome Scale

Secondary outcome: Antipsychotic Adverse Event Form

Detailed description: Eighty individuals with MAP will be randomly assigned into two treatment groups, i. e. treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. The doses will be increased every 5 days until no psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic adverse events will be checked and documented daily.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Having a psychotic episode with current use of methamphetamine

- Positive urine toxicology test for methamphetamine on the first day of

hospitalization Exclusion Criteria:

- Using other illegal substances

- Having a history of primary psychotic disorders or using antipsychotic agents

- Having a chronic medical disease, e. g. essential hypertension, diabetes, epilepsy,

stroke

Thanyarak Institute on Drug Abuse, Pathumthani, Thailand

Starting date: March 2010
Last updated: September 5, 2013